Raffles Medical (RM) just announced its Q2 2017 results.
At first glance, RM’s Revenue, Ops Income and Net Income for Q2 remained constant or showed marginal fall over Q1 respectively: 1%, -1.9%, -2.3%.
Its Net Cashflow from Ops of $23.6m is similar to the $23.8m in Q1.
Balance sheet remains strong, with $112m cash and only $53m loans and borrowings.
All in all, results seem fine.
But its share price is a different story. It dropped about 5% to $1.21 on 1 Aug, one day after its result release, and fell further to $1.185 on 2 Aug afternoon. That is about an 8% drop since result announcement.
This piqued my interest. RM has been on my watch list for long and I am interested to know if this is a good chance to start accumulating the shares.
RM Traded at …